ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890

Its studies are mostly in Colorectal Neoplasms, led by Incyte.

Drug pageAnti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Dec 9, 20253 company-led studies, 3 open or runningNext primary completion: Dec 29, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Incyte33 open or runningphase 3since Dec 9, 2025Apr 14, 2023Dec 29, 2028phase 3 · NCT07284849

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 14, 2023First study: phase 1 study in Solid TumorsFirst studyNCT05836324 · 570 planned · United States, China, Denmark and more
  2. Dec 9, 2025Phase 3 study in Colorectal NeoplasmsPhase 3 reachedNCT07284849 · 700 planned · United States, Argentina, Australia and more
  3. Sep 11, 2026Phase 2 study in Colorectal NeoplasmsNCT07823322 · 40 planned · United States, Puerto Rico

Ahead

  1. Dec 29, 2028Primary completion: phase 3 study in Colorectal NeoplasmsNCT07284849
  2. May 3, 2029Primary completion: phase 1 study in Solid TumorsNCT05836324
  3. May 14, 2029Primary completion: phase 2 study in Colorectal NeoplasmsNCT07823322

TargetBeta

PDCD1 →TGFB1 →read by rule
“A bispecific antibody directed against the human negative immunoregulatory checkpoint receptor programmed cell death protein 1 (PD-1; PD1; PDCD1; CD279) and human transforming growth factor beta (TGF-beta) receptor II (TGFbRII), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868Sino Biopharmaceuticalphase 34

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07823322Colorectal Neoplasms · United States, Puerto Rico2RecruitingMay 14, 202940
NCT07284849Colorectal Neoplasms · United States, Argentina, Australia and more3RecruitingDec 29, 2028700
NCT05836324Solid Tumors · United States, China, Denmark and more1RecruitingMay 3, 2029570

How it is read

Names in the registry

  • “INCA33890”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.